AUSTIN, Texas and HAMILTON, ON and SAN DIEGO, March 12, 2025 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics ...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the ...
The TAC technology platform, demonstrated by TAC01-CLDN18.2, reprograms T cells to harness the natural T cell receptor (TCR) signaling complex, enabling precise tumor targeting while minimizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback